The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Petrov S.Iu.

FGBU "NII glaznykh bolezneĭ" RAMN

Zinina V.S.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Volzhanin A.V.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

The role of fixed dose combinations in the treatment of primary open-angle glaucoma

Authors:

Petrov S.Iu., Zinina V.S., Volzhanin A.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2018;134(4): 100‑107

DOI: 10.17116/oftalma2018134041100

Read: 3998 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF FIXED DOSE COMBINATIONS IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA
THE ROLE OF FIXED DOSE COMBINATIONS IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA

To cite this article:

Petrov SIu, Zinina VS, Volzhanin AV. The role of fixed dose combinations in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2018;134(4):100‑107. (In Russ.)
https://doi.org/10.17116/oftalma2018134041100

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effi­cacy and safety of the fixed combination of dorzolamide/timolol (Dorzotimol) in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2024;(5):125-129
Long-term outcomes of phakic intraocular lens implantation in high myopia. Russian Annals of Ophthalmology. 2025;(1):28-31
Cost-effectiveness of using rubi­dium-82 chlo­ride perfusion PET for planning myocardial reva­scularization procedures. Piro­gov Russian Journal of Surgery. 2024;(12-2):58-65
Abstract:

A great number of patients with primary open-angle glaucoma require combination therapy with several hypotensive drugs of different pharmacological groups to efficiently compensate the intraocular pressure (IOP) and prevent further development of glaucoma. Although glaucoma treatment usually starts with monotherapy, several preparations administered simultaneously have stronger hypotensive effect further increased by their additive action. However, the increased frequency of instillations may lead to drug washout and decreased patient compliance. Fixed dose combinations (FDCs) are a pharmacological form of eye drops that combines two or more active drugs in a single dosage form. The frequency of FDCs administration does not exceed two per day, which is convenient for long-term application and helps improve patient compliance. FDCs tolerability tends to be higher than that of simultaneous instillations of separate monotherapy drugs, while the hypotensive in clinical trials is comparable, in some real practice trials is superior. A review of existing studies showed that FDCs are superior to monotherapy in terms of cost-effectiveness. The use of FDCs was found to be beneficial for glaucoma treatment from the viewpoints of both reaching the target IOP for preserving visual functions in glaucoma patients, and minimizing the long-term treatment costs.

Keywords:

open-angle glaucoma
fixed dose combinations
cost-effectiveness
intraocular pressure

Authors:

Petrov S.Iu.

FGBU "NII glaznykh bolezneĭ" RAMN

Zinina V.S.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Volzhanin A.V.

Research Institute of Eye Diseases, 11, A, B, Rossolimo St., Moscow, Russian Federation, 119021

Close metadata

References:

  1. Nesterov AP, Alekseev VN, Alekseev IB, Amirov AN, Astakhov YuS, Balalin SV. Natsional’noe rukovodstvo po glaukome dlya praktikuyuschikh vrachei. 3 izdanie, isprav. i dop. M.: GEOTAR-Media; 2015. (In Russ.)
  2. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th edition ed: Savona, Italy PubliComm; 2014.
  3. Erichev VP, Egorov EA. Vestnik oftal’mologii. 2014;130(6):98-105. (In Russ.)
  4. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Archives of ophthalmology. 2002;120(6):714-720; discussion 829-730.
  5. Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE, Canadian Glaucoma Study G. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Archives of ophthalmology. 2008;126(8):1030-1036. https://doi.org/10.1001/archopht.126.8.1030
  6. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology. 2002;120(10):1268-1279.
  7. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of ophthalmology. 2002;120(6):701-713; discussion 829-730.
  8. Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs & aging. 2008;25(9):729-759.
  9. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. Journal of glaucoma. 2009;18(3):238-243. https://doi.org/10.1097/IJG.0b013e3181815421
  10. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs & aging. 2007;24(12):1007-1016.
  11. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. Journal of pharmaceutical sciences. 1974;63(3):333-338.
  12. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953-961. https://doi.org/10.1016/j.ophtha.2004.12.035
  13. Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clinical ophthalmology. 2010;4:1-9.
  14. Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. The British journal of ophthalmology. 2008;92(6):729-734. https://doi.org/10.1136/bjo.2008.139329
  15. Scharrer A, Ober M. Metipranolol 0.1% and pilocarpine 2% as a fixed combination compared to each substance alone in the treatment of glaucoma. A controlled, randomized clinical study comparing the intraindividual effects and tolerance. Klinische Monatsblatter fur Augenheilkunde. 1986;189(6):450-455. https://doi.org/10.1055/s-2008-1050851
  16. Bron AM, Garcher CP, Sirbat D, Allaire CM, Lablache-Combier MJ, Trinquand CJ. Comparison of two fixed beta-blocker-pilocarpine combinations. The Carteolol-Pilocarpine Study Group. European journal of ophthalmology. 1997;7(4):351-356.
  17. Demailly P, Allaire C, Bron V, Trinquand C. Effectiveness and Tolerance of beta-Blocker/Pilocarpine Combination Eye Drops in Primary Open-Angle Glaucoma and High Intraocular Pressure. Journal of glaucoma. 1995;4(4):235-241.
  18. Puustjarvi TJ, Repo LP. Timolol-pilocarpine fixed-ratio combinations in the treatment of chronic open angle glaucoma. A controlled multicenter study of 48 weeks. Scandinavian Timpilo Study Group. Archives of ophthalmology. 1992;110(12):1725-1729.
  19. Robin AL. Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. Transactions of the American Ophthalmological Society. 1996;94:89-101; discussion 101-103.
  20. Podos SM, Camras CB, Serle JB. Experimental compounds to lower intraocular pressure. Australian and New Zealand journal of ophthalmology. 1989;17(2):129-135.
  21. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert opinion on pharmacotherapy. 2000;1(4):815-834. https://doi.org/10.1517/14656566.1.4.815
  22. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Survey of ophthalmology. 2008;53(suppl 1):107-120. https://doi.org/10.1016/j.survophthal.2008.08.010
  23. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Current pharmaceutical design. 2008;14(7):649-654.
  24. Konstas AG, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN, Stewart WC. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Archives of ophthalmology. 2005;123(7):898-902. https://doi.org/10.1001/archopht.123.7.898
  25. Konstas AG, Tsironi S, Vakalis AN, Nasr MB, Stewart JA, Nelson LA, Stewart WC. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta ophthalmologica. 2009;87(1):71-76. https://doi.org/10.1111/j.1755-3768.2007.01145.x
  26. Bagga H, Liu JH, Weinreb RN. Intraocular pressure measurements throughout the 24 h. Current opinion in ophthalmology. 2009;20(2):79-83. https://doi.org/10.1097/ICU.0b013e32831eef4f
  27. Konstas AG, Hollo G, Mikropoulos D, Tsironi S, Haidich AB, Embeslidis T, Georgiadou I, Irkec M, Melamed S. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. The British journal of ophthalmology. 2010;94(2):209-213. https://doi.org/10.1136/bjo.2008.155317
  28. Diestelhorst M, Larsson LI, European-Canadian Latanoprost Fixed Combination Study G. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113(1):70-76. https://doi.org/10.1016/j.ophtha.2005.06.027
  29. Diestelhorst M, Larsson LI, European Latanoprost Fixed Combination Study G. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. The British journal of ophthalmology. 2004;88(2):199-203.
  30. Konstas AG, Mikropoulos D, Kaltsos K, Jenkins JN, Stewart WC. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology. 2006;113(3):446-450. https://doi.org/10.1016/j.ophtha.2005.10.053
  31. Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics. 2002;18(5):401-409. https://doi.org/10.1089/10807680260362687
  32. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic surgery. 1995;26(3):233-236.
  33. Dunker S, Schmucker A, Maier H, Latanoprost/Timolol Fixed Combination Study G. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Advances in therapy. 2007;24(2):376-386.
  34. Kazanova SYu, Strakhov VV. Analysis of glaucoma process progression rates depending on various treatment non-compliance scenarios. Natsional’nyi zhurnal glaukoma. 2016;15(2):74-83. (In Russ.)
  35. Higginbotham EJ, Hansen J, Davis EJ, Walt JG, Guckian A. Glaucoma medication persistence with a fixed combination versus multiple bottles. Current medical research and opinion. 2009;25(10):2543-2547. https://doi.org/10.1185/03007990903260129
  36. Primary Open-angle Glaucoma, Preferred Practice Pattern. Ophthalmology A.A.o., editor2005.
  37. Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I, Ganfort Investigators G, II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. Journal of glaucoma. 2008;17(3):211-216. https://doi.rg/o10.1097/IJG.0b013e3181507313
  38. Hommer A, Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. European journal of ophthalmology. 2007;17(1):53-62.
  39. Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Archives of ophthalmology. 2006;124(9):1230-1238. https://doi.org/10.1001/archopht.124.9.1230
  40. Mandić Z, Novak-Laus K, Bojić L, et al. Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%/timolol 0.5%) in 6 months follow up period. Acta Clin Croat. 2010;49(4):411-419.
  41. Erichev VP, Filippova OM, Lovpache DN, Vasilenkova LV. Dry eye syndrome and local hypotensive therapy. Glaukoma. 2002;2:40. (In Russ.)
  42. Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA, Bergamini MV. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. American journal of ophthalmology. 2005;140(1):1-7. https://doi.org/10.1016/j.ajo.2005.02.043
  43. Goni FJ, Brimonidine/Timolol Fixed Combination Study G. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. European journal of ophthalmology. 2005;15(5):581-590.
  44. Hommer A, Thygesen J, Ferreras A, Wickstrom J, Friis MM, Buchholz P, Walt JG. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma. European journal of ophthalmology. 2008;18(5):778-786.
  45. Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. The British journal of ophthalmology. 1998;82(11):1249-1253.
  46. Lazaridou MN, Montgomery DM, Ho WO, Jaberoo D. Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Current medical research and opinion. 2008;24(10):2725-2728. https://doi.org/10.1185/03007990802312567
  47. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1936-1944.
  48. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. American journal of ophthalmology. 1998;126(4):487-497.
  49. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. American journal of ophthalmology. 2000;130(4):429-440.
  50. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, Early Manifest Glaucoma Trial G. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Archives of ophthalmology. 2003;121(1):48-56.
  51. Kurysheva NI, Shatalova EO. Evolution of concepts of role of intraocular pressure in glaucoma progression (review). Oftal’mologiy. 2016;13(3):135-143. (In Russ.) https://doi.org/10.18008/1816-5095-2016-3-135-143
  52. Kuroyedov AV. Clinical and economic approaches to the glaucoma patients treatment. Oftal’mol vedomosti. 2010;3(1):51-62. (In Russ.)
  53. Kuroyedov AV, Abysheva LD, Avdeev RV, Alexandrov AS, Basinsky AS, Blyum EA, Brezhnev AYu, Gazizova IR, Galimova AB, Gaponko OV, Garkavenko VV, Getmanova AM, Gorodnichy VV, Gorshkova MS, Gusarevitch AA, Diordiychuk SV, Dorofeev DA, Zhavoronkov SA, Zavadsky PCh, Zakhidov AB, Zvereva OG, Karimov UR, Kulik AV, Lanin SN, Lovpache DzhN, Loskutov IA, Molchanova EV, Nefedov NA, Ogorodnikova VYu, Onufrichuk ON, Petrov SYu, Rozhko YuI, Sidenko TA, Tashtitova LB, Khudzhatova MS. Medico-economic multicenter study of local hypotensive therapy efficacy and cost for patients with primary open-angle glaucoma in CIS. Oftal’mologij Vostochnay Evropa. 2015;3(26):35-51. (In Russ.)
  54. Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, Nordmann JP, Renard JP, Bayer A, Grehn F, Pfeiffer N, Cedrone C, Gandolfi S, Orzalesi N, Nucci C, Rossetti L, Azuara-Blanco A, Bagnis A, Hitchings R, Salmon JF, Bricola G, Buchholz PM, Kotak SV, Katz LM, Siegartel LR, Doyle JJ. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. The British journal of ophthalmology. 2005;89(10):1245-1249. https://doi.org/10.1136/bjo.2005.067355
  55. Lindblom B, Nordmann JP, Sellem E, Chen E, Gold R, Polland W, Williamson W, Buchholz P, Walt JG, Groleau D, Curry A, Evans SJ. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta ophthalmologica Scandinavica. 2006;84(1):74-83. https://doi.org/10.1111/j.1600-0420.2005.00560.x
  56. Lee PP, Walt JG, Doyle JJ, Kotak SV, Evans SJ, Budenz DL, Chen PP, Coleman AL, Feldman RM, Jampel HD, Katz LJ, Mills RP, Myers JS, Noecker RJ, Piltz-Seymour JR, Ritch RR, Schacknow PN, Serle JB, Trick GL. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Archives of ophthalmology. 2006;124(1):12-19. https://doi.org/10.1001/archopht.124.1.12
  57. Bramley T, Peeples P, Walt JG, Juhasz M, Hansen JE. Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma. Archives of ophthalmology. 2008;126(6):849-856. https://doi.org/10.1001/archopht.126.6.849
  58. Ström O. Medical costs of glaucoma in Sweden. International Society For Pharmacoeconomics and Outcomes Research (ISPOR). Toronto, Ontario, Canada, 3—7 May 2008.
  59. Nordmann JP, Lafuma A, Deschaseaux C, Berdeaux G. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. Journal of glaucoma. 2005;14(6):463-469.
  60. van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, Schouten JS. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol. 2012;90(1):20-31.
  61. Tuil E, Hommer AB, Poulsen PB, Christensen TL, Buchholz P, Walt J, Holmstrom S. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients — a European perspective. International journal of clinical practice. 2005;59(9):1011-1016. https://doi.org/10.1111/j.1742-1241.2005.00616.x
  62. Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clinical ophthalmology. 2011;5:291-298. https://doi.org/10.2147/OPTH.S16355
  63. Hommer A, Hubatsch DA, Cano-Parra J. Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma. J Ophthalmol. 2015;131970. https://doi.org/10.1155/2015/131970
  64. Konstas AG, Hollo G, Haidich AB, Mikropoulos DG, Giannopoulos T, Voudouragkaki IC, Paschalinou E, Konidaris V, Samples JR. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2013;29(7):652-657. https://doi.org/10.1089/jop.2012.0195
  65. Pachimkul P, Yuttitham K, Thoophom P. 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension. J Med Assoc Thai. 2011;94(suppl 2):81-87.
  66. Scherzer ML, Liehneova I, Negrete FJ, Schnober D. Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%. Advances in therapy. 2011;28(8):661-670. https://doi.org/10.1007/s12325-011-0043-z
  67. Konstas AG, Voudouragkaki IC, Boboridis KG, Haidich AB, Paschalinou E, Giannopoulos T, Dragoumis ND, Makridis AK, Kahook MY. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost. Advances in therapy. 2014;31(6):592-603. https://doi.org/10.1007/s12325-014-0125-9
  68. Lerner SF, Park KH, Hubatsch DA, Erichev VP, Pachka JA, Roberts TV. Efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination for the treatment of primary open-angle glaucoma or ocular hypertension inadequately controlled with beta-blocker monotherapy. Natsional’nyi zhurnal glaukoma. 2017;16(3):18-27. (In Russ.)
  69. Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Advances in therapy. 2014;31(12):1213-1227. https://doi.org/10.1007/s12325-014-0168-y
  70. Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014;121(12):2348-2355. https://doi.org/10.1016/j.ophtha.2014.06.022
  71. Nguyen QH, McMenemy MG, Realini T, Whitson JT, Goode SM. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics. 2013;29(3):290-297. https://doi.org/10.1089/jop.2012.0235
  72. Sharma S, Trikha S, Perera SA, Aung T. Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clinical ophthalmology. 2015;9:2201-2207. https://doi.org/10.2147/OPTH.S72380
  73. Greig SL, Deeks ED. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Drugs & aging. 2015;32(3):251-260. https://doi.org/10.1007/s40266-015-0250-4
  74. Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Current medical research and opinion. 2009;25(7):1645-1653. https://doi.org/10.1185/03007990902994041
  75. Konstas AG, Holló G, Haidich AB, Mikropoulos DG, Giannopoulos T, Voudouragkaki IC, Paschalinou E, Konidaris V, Samples JR. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy. J Ocul Pharmacol Ther. 2013;29(7):652-657. Epub 2013 Apr 3. https://doi.org/10.1089/jop.2012.0195
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.